Assertio Therapeutics (ASRT) Tops Q4 EPS by 11c

Assertio Therapeutics (NASDAQ: ASRT) reported Q4 EPS of $0.32, $0.11 better than the analyst estimate of $0.21. Revenue for the quarter came in at $50.35 million versus the consensus estimate of $46.71 million.

For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• MP Materials seen largely insulated after China export-control move
• Goldman reinstates Estee Lauder rating, sees turnaround driving growth and margins